21st North Inc (ULGX)
21st North Inc, trading on OTC Markets under the symbol ULGX, is a common stock listing associated with a healthcare company focused on minimally invasive treatments for benign prostatic hyperplasia (BPH). The business develops, manufactures, markets, and distributes medical products in the United States aimed at relieving urinary obstruction and related symptoms caused by BPH. Its product portfolio includes Cooled ThermoTherapy, which combines microwave energy with cooling technology to help protect surrounding tissue and improve patient comfort, and the Prostiva RF Therapy System, which uses radio frequency energy to target prostate tissue and reduce urethral constriction. The company serves patients and clinicians and was founded in 1991. It is based in Minneapolis, Minnesota.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ULGX
|
—
|
—
|
—
|
—
|
—
|
—
|
Good
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
2.128 K
|
—
|
—
|
—
|
—
|
—
|
—
|